Summary
Conducting clinical trials in rare diseases and advancing research pipelines requires a collaborative, multi-stakeholder approach. This process requires cooperation from industry, academic researchers, advocacy groups, and patients as well as their caregivers and families. In this white paper, we look at the barriers drug developers face when positioning a new trial in the rare disease space and how to minimize these barriers by applying a multi-stakeholder collaborative approach to drug development.
Register to download
Multi-Stakeholder Collaborations Can Minimize Barriers & Drive Rare Disease Clinical Programs to Better Patient Outcomes
You may also be interested in:
White Paper
The Patient Voice: Engaging Rare Disease Patients Improves Clinical Trial Enrollment & Retention
Clinical trials in rare diseases are complex and present unique challenges. However, patients in these trials are very vocal, with caretakers, family…
Poster
A Blueprint to Success: Onboarding a Medical Writer
Onboarding is the process of welcoming new employees into an organization and providing them with the tools, resources, and knowledge to become…
White Paper
Clinical Trials in Children with Impaired Mental Capacity
Download this resource to learn how to conduct studies with patients who lack legal competence and the 4 ethical pillars of medical research.